Select a topic () of interest
- Management of M0 muscle-invasive bladder cancer beyond radical cystectomy
- Variant histology = radical cystectomy, right?
- New hope for patients progressing after first-line treatment for mUCa
- It’s getting personalised: first-line therapy of synchronous or metachronous mUCa
- Immunotherapy: handling AEs and special populations
- Challenges in high-risk NMIBC
- Low- and intermediate-risk NMIBC: surveillance or intravesical therapy?
- Follow-up surveillance regimes for low-/intermediate-risk NMIBC
- Follow-up surveillance regimes to consider for (very) high-risk NMIBC and MIBC